Inhibition of inflammation-mediated DPP-4 expression by linagliptin increases M2 macrophages in atherosclerotic lesions

This publication has 26 references indexed in Scilit:

• Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis
  Circulation, 2011
• Telmisartan Exerts Antiatherosclerotic Effects by Activating Peroxisome Proliferator-Activated Receptor-γ in Macrophages
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2011
• DPP-4 Inhibitors
  Diabetes Care, 2011
• Human Atherosclerotic Plaque Alternative Macrophages Display Low Cholesterol Handling but High Phagocytosis Because of Distinct Activities of the PPARγ and LXRα Pathways
  Circulation Research, 2011
• Identification of a Novel Macrophage Phenotype That Develops in Response to Atherogenic Phospholipids via Nrf2
  Circulation Research, 2010
• The role of gut hormones in glucose homeostasis
  Journal of Clinical Investigation, 2007
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
  The Lancet, 2006
• Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV
  Critical Reviews in Clinical Laboratory Sciences, 2003
• Regulation of CD26/DPPIV gene expression by interferons and retinoic acid in tumor B cells
  Oncogene, 2000
• Atherosclerosis — An Inflammatory Disease
  New England Journal of Medicine, 1999